Research programme: antibody-drug conjugates - Adimab/Mersana Therapeutics

Drug Profile

Research programme: antibody-drug conjugates - Adimab/Mersana Therapeutics

Alternative Names: Fleximer®-ADC - Adimab/Mersana Therapeutics; Trastuzumab-m-Dolaflexin®; Trastuzumab-s-Dolaflexin®; XMT-1535; XMT-1536

Latest Information Update: 10 Mar 2017

Price : $50

At a glance

  • Originator Adimab; Mersana Therapeutics
  • Class Antineoplastics; Depsipeptides; Drug conjugates; Immunoconjugates
  • Mechanism of Action Immunomodulators; Type IIb sodium-phosphate cotransporter protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Non-small cell lung cancer

Most Recent Events

  • 09 Mar 2017 Mersana Therapeutics has patent protection for Fleximer-ADC platform technology in the European Union
  • 05 Dec 2016 Pharmacodynamics data from a preclinical study inNon-small cell lung cancer released by Mersana Therapeutics
  • 05 Dec 2016 Mersana Therapeutics and Asimab plans a clinical trial for Cancer in
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top